Omnicell, Inc. (NASDAQ:OMCL) Receives $59.86 Consensus Price Target from Analysts

Shares of Omnicell, Inc. (NASDAQ:OMCL) have earned an average recommendation of “Moderate Buy” from the nine ratings firms that are presently covering the stock, MarketBeat.com reports. Two analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 1 year target price among brokers that have covered the stock in the last year is $59.8571.

Several analysts recently weighed in on OMCL shares. Wall Street Zen raised Omnicell from a “buy” rating to a “strong-buy” rating in a research note on Sunday, May 10th. KeyCorp boosted their target price on Omnicell from $60.00 to $70.00 and gave the stock an “overweight” rating in a research note on Tuesday, April 28th. Wells Fargo & Company increased their target price on shares of Omnicell from $52.00 to $55.00 and gave the stock an “overweight” rating in a report on Thursday, April 23rd. Zacks Research lowered shares of Omnicell from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 7th. Finally, Weiss Ratings raised shares of Omnicell from a “sell (d)” rating to a “hold (c-)” rating in a research note on Thursday, May 7th.

Omnicell Stock Down 3.8%

NASDAQ OMCL opened at $41.40 on Monday. The business has a fifty day moving average price of $42.29 and a two-hundred day moving average price of $41.23. The stock has a market capitalization of $1.88 billion, a PE ratio of 94.09, a PEG ratio of 1.11 and a beta of 0.96. Omnicell has a fifty-two week low of $28.90 and a fifty-two week high of $55.00. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.50 and a quick ratio of 1.29.

Omnicell (NASDAQ:OMCL) last issued its quarterly earnings results on Tuesday, April 28th. The company reported $0.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.33 by $0.22. Omnicell had a return on equity of 4.00% and a net margin of 1.67%.The company had revenue of $309.88 million for the quarter, compared to analyst estimates of $304.02 million. During the same quarter last year, the company posted $0.26 EPS. The company’s revenue for the quarter was up 14.9% compared to the same quarter last year. Equities analysts expect that Omnicell will post 1.31 earnings per share for the current fiscal year.

Insider Buying and Selling at Omnicell

In other news, EVP Nnamdi Njoku sold 3,090 shares of the stock in a transaction on Monday, May 18th. The stock was sold at an average price of $43.22, for a total value of $133,549.80. Following the completion of the transaction, the executive vice president directly owned 154,785 shares in the company, valued at approximately $6,689,807.70. This represents a 1.96% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Corey J. Manley sold 5,025 shares of the firm’s stock in a transaction on Monday, May 18th. The shares were sold at an average price of $43.22, for a total value of $217,180.50. Following the sale, the executive vice president directly owned 112,783 shares in the company, valued at approximately $4,874,481.26. This trade represents a 4.27% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 2.92% of the stock is currently owned by corporate insiders.

Institutional Trading of Omnicell

A number of hedge funds have recently made changes to their positions in the company. Raymond James Financial Inc. bought a new position in Omnicell in the 2nd quarter valued at approximately $26,000. Versant Capital Management Inc grew its holdings in Omnicell by 38.7% during the 2nd quarter. Versant Capital Management Inc now owns 1,053 shares of the company’s stock worth $44,000 after acquiring an additional 294 shares during the last quarter. Clearstead Advisors LLC grew its holdings in Omnicell by 12,180.0% during the 4th quarter. Clearstead Advisors LLC now owns 1,228 shares of the company’s stock worth $56,000 after acquiring an additional 1,218 shares during the last quarter. Kemnay Advisory Services Inc. acquired a new position in Omnicell in the 4th quarter valued at approximately $58,000. Finally, Parkside Financial Bank & Trust raised its stake in shares of Omnicell by 1,708.1% during the fourth quarter. Parkside Financial Bank & Trust now owns 1,338 shares of the company’s stock valued at $61,000 after acquiring an additional 1,264 shares during the last quarter. 97.70% of the stock is owned by institutional investors and hedge funds.

About Omnicell

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.